Literature DB >> 24072851

Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?

Valeria Santini1, Jennifer Schemenau, Alessandro Levis, Enrico Balleari, Rosa Sapena, Lionel Adès, Agnès Guerci, Odile Beyne-Rauzy, Marie-Pierre Gourin, Stephane Cheze, Aspasia Stamatoullas, Alessandro Sanna, Daniela Gioia, Gianni Cametti, Dario Ferrero, Emmanuel Raffoux, Christian Rose, Antonella Poloni, Thomas Prebet, Laurence Legros, Shanti Natarajan-Amé, Pierre Fenaux, Ulrich Germing, François Dreyfus, Sophie Park.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24072851     DOI： 10.1182/blood-2013-07-512442

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  14 in total

1.  Personalized medicine in myelodysplastic syndromes: wishful thinking or already clinical reality?

Authors:  Uwe Platzbecker; Pierre Fenaux
Journal:  Haematologica       Date:  2015-05       Impact factor: 9.941

2.  Effects of erythropoiesis-stimulating agents on overall survival of International Prognostic Scoring System Low/Intermediate-1 risk, transfusion-independent myelodysplastic syndrome patients: a cohort study.

Authors:  Emanuela Messa; Daniela Gioia; Elisa Masiera; Anna Castiglione; Manuela Ceccarelli; Flavia Salvi; Paolo Danise; Alessandro Sanna; Bernardino Allione; Enrico Balleari; Antonella Poloni; Giovanni Cametti; Dario Ferrero; Rodolfo Tassara; Carlo Finelli; Margherita Bonferroni; Pellegrino Musto; Giuseppe Saglio; Alessandro Levis; Valeria Santini
Journal:  Haematologica       Date:  2018-08-03       Impact factor: 9.941

3.  Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?

Authors:  Olivier Kosmider; Marie Passet; Valeria Santini; Uwe Platzbecker; Valérie Andrieu; Gina Zini; Odile Beyne-Rauzy; Agnès Guerci; Erico Masala; Enrico Balleari; Ekaterina Bulycheva; François Dreyfus; Pierre Fenaux; Michaela Fontenay; Sophie Park
Journal:  Haematologica       Date:  2016-04-07       Impact factor: 9.941

Review 4.  Current treatment algorithm for the management of lower-risk MDS.

Authors:  Aristoteles Giagounidis
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 5.  Treatment of low-risk myelodysplastic syndromes.

Authors:  Valeria Santini
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

6.  A randomized controlled trial comparing darbepoetin alfa doses in red blood cell transfusion-dependent patients with low- or intermediate-1 risk myelodysplastic syndromes.

Authors:  Jun Ho Jang; Hironori Harada; Hirohiko Shibayama; Ryutaro Shimazaki; Hyeoung-Joon Kim; Kenichi Sawada; Kinuko Mitani
Journal:  Int J Hematol       Date:  2015-09-01       Impact factor: 2.490

Review 7.  Setting Fire to ESA and EMA Resistance: New Targeted Treatment Options in Lower Risk Myelodysplastic Syndromes.

Authors:  Anne Sophie Kubasch; Uwe Platzbecker
Journal:  Int J Mol Sci       Date:  2019-08-07       Impact factor: 5.923

8.  Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes.

Authors:  Sophie Park; Olivier Kosmider; Frédéric Maloisel; Bernard Drenou; Nicolas Chapuis; Thibaud Lefebvre; Zoubida Karim; Hervé Puy; Anne Sophie Alary; Sarah Ducamp; Frédérique Verdier; Cécile Bouilloux; Alice Rousseau; Marie-Christine Jacob; Agathe Debliquis; Agnes Charpentier; Emmanuel Gyan; Bruno Anglaret; Cecile Leyronnas; Selim Corm; Borhane Slama; Stephane Cheze; Kamel Laribi; Shanti Amé; Christian Rose; Florence Lachenal; Andrea Toma; Gian Matteo Pica; Martin Carre; Frédéric Garban; Clara Mariette; Jean-Yves Cahn; Mathieu Meunier; Olivier Herault; Pierre Fenaux; Orianne Wagner-Ballon; Valerie Bardet; Francois Dreyfus; Michaela Fontenay
Journal:  Haematologica       Date:  2018-10-04       Impact factor: 9.941

9.  Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score-matched analysis.

Authors:  Enrico Balleari; Rosa Angela Filiberti; Chiara Salvetti; Bernardino Allione; Emanuele Angelucci; Marco Bruzzone; Tullio Calzamiglia; Marina Cavaliere; Maurizio Cavalleri; Daniela Cilloni; Marino Clavio; Elena Crisà; Anna Da Col; Paolo Danise; Federica Pilo; Dario Ferrero; Carlo Finelli; Daniela Gioia; Roberto Massimo Lemoli; Elisa Masiera; Emanuela Messa; Maurizio Miglino; Pellegrino Musto; Esther Natalie Oliva; Antonella Poloni; Flavia Salvi; Alessandro Sanna; Marco Scudeletti; Rodolfo Tassara; Valeria Santini
Journal:  Cancer Med       Date:  2019-10-27       Impact factor: 4.452

Review 10.  Treatment of Anemia in Transfusion-Dependent and Non-Transfusion-Dependent Lower-Risk MDS: Current and Emerging Strategies.

Authors:  Ulrich Germing; Ester N Oliva; Devendra Hiwase; Antonio Almeida
Journal:  Hemasphere       Date:  2019-10-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.